<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
16.05.2019 14:59:58

Press Release: Novartis data at ASCO and EHA -3-

** Capmatinib (INC280) is an investigational, oral and selective MET

inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the

Agreement, Incyte granted Novartis worldwide exclusive development and

commercialization rights to capmatinib and certain back-up compounds in

(Anzeige)Passende neue Barrier Reverse Convertibles

all indications.

*** Novartis and the University of Pennsylvania's Perelman School of

Medicine (Penn) have a global collaboration to research, develop and

commercialize chimeric antigen receptor T cell (CAR-T) therapies,

including Kymriah, for the investigational treatment of cancers.

**** Lutathera is a registered trademark of Advanced Accelerator

Applications, a Novartis company.

***** Jakavi is a registered trademark of Novartis AG in countries

outside the United States. Jakafi is a registered trademark of Incyte

Corporation. Novartis licensed ruxolitinib from Incyte Corporation for

development and commercialization outside the United States.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Antonio Ligi Julie Masow

Novartis Global Media Relations Novartis Oncology Media Relations

+41 61 324 1374 (direct) +1 862 778 7220 (direct)

+41 79 723 3681 (mobile) +1 862 579 8456 (mobile)

antonio.ligi@novartis.com julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Novartis Pharma AG Novartis

Pharmaceuticals

Corporation

CH-4002 Basel (c) 2019 Novartis 5/19 G-ONC-1211773 East Hanover, New

Switzerland Jersey

07936-1080

Media release (PDF): http://hugin.info/134323/R/2244502/886389.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

May 16, 2019 09:00 ET (13:00 GMT)